File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: How do we safely get people to stop smoking?

TitleHow do we safely get people to stop smoking?
Authors
Issue Date2011
PublisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerpreventionresearch.aacrjournals.org/
Citation
Cancer Prevention Research, 2011, v. 4 n. 11, p. 1724-1727 How to Cite?
AbstractNicotine replacement therapy (NRT) is a valuable, proven, and U.S. Food and Drug Administration-approved tool for smoking cessation. However, the discoveries of functional nicotinic acetylcholine receptors (nAChR) on lung epithelial and cancer cells and of nAChR polymorphisms associated with lung cancer risk, in addition to a large number of preclinical studies indicating that nicotine may promote or facilitate cancer development and growth, have prompted concern that NRT, although important for smoking cessation, may actually augment lung carcinogenesis. Therefore, it is of great public health interest that two independent studies reported in this issue of the journal (Murphy and colleagues, beginning on page 1752, and Maier and colleagues, beginning on page 1743) showed that nicotine given in drinking water at a dose to achieve blood concentrations in mice similar to those achieved in people receiving NRT did not enhance lung carcinogenesis or tumor growth in several mouse models of lung cancer. Effective non-nicotine alternatives to NRT, such as varenicline and bupropion, are also available and perhaps better than NRT for smoking cessation therapy. In the near future, nicotine vaccines will likely be added to the smoking cessation armamentarium. However, the normal and pathophysiologic role of nicotine, nAChRs, and the signaling pathways they activate in lung epithelial cells and lung cancer still requires elucidation.
Persistent Identifierhttp://hdl.handle.net/10722/163417
ISSN
2015 Impact Factor: 3.887
2015 SCImago Journal Rankings: 2.374
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLam, CLDen_US
dc.contributor.authorMinna, JDen_US
dc.date.accessioned2012-09-05T05:31:08Z-
dc.date.available2012-09-05T05:31:08Z-
dc.date.issued2011en_US
dc.identifier.citationCancer Prevention Research, 2011, v. 4 n. 11, p. 1724-1727en_US
dc.identifier.issn1940-6207en_US
dc.identifier.urihttp://hdl.handle.net/10722/163417-
dc.description.abstractNicotine replacement therapy (NRT) is a valuable, proven, and U.S. Food and Drug Administration-approved tool for smoking cessation. However, the discoveries of functional nicotinic acetylcholine receptors (nAChR) on lung epithelial and cancer cells and of nAChR polymorphisms associated with lung cancer risk, in addition to a large number of preclinical studies indicating that nicotine may promote or facilitate cancer development and growth, have prompted concern that NRT, although important for smoking cessation, may actually augment lung carcinogenesis. Therefore, it is of great public health interest that two independent studies reported in this issue of the journal (Murphy and colleagues, beginning on page 1752, and Maier and colleagues, beginning on page 1743) showed that nicotine given in drinking water at a dose to achieve blood concentrations in mice similar to those achieved in people receiving NRT did not enhance lung carcinogenesis or tumor growth in several mouse models of lung cancer. Effective non-nicotine alternatives to NRT, such as varenicline and bupropion, are also available and perhaps better than NRT for smoking cessation therapy. In the near future, nicotine vaccines will likely be added to the smoking cessation armamentarium. However, the normal and pathophysiologic role of nicotine, nAChRs, and the signaling pathways they activate in lung epithelial cells and lung cancer still requires elucidation.en_US
dc.languageengen_US
dc.publisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerpreventionresearch.aacrjournals.org/en_US
dc.relation.ispartofCancer Prevention Researchen_US
dc.subject.meshAdenocarcinoma - etiology-
dc.subject.meshAdenoma - drug therapy-
dc.subject.meshCarcinogens - toxicity-
dc.subject.meshCell Transformation, Neoplastic - pathology-
dc.subject.meshDisease Models, Animal-
dc.titleHow do we safely get people to stop smoking?en_US
dc.typeArticleen_US
dc.identifier.emailLam, DCL: dcllam@hku.hken_US
dc.identifier.authorityLam, DCL=rp01345en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1158/1940-6207.CAPR-11-0449en_US
dc.identifier.pmid22052339-
dc.identifier.pmcidPMC3372398-
dc.identifier.scopuseid_2-s2.0-81555195424en_US
dc.identifier.hkuros202195-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-81555195424&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume4en_US
dc.identifier.issue11en_US
dc.identifier.spage1724en_US
dc.identifier.epage1727en_US
dc.identifier.isiWOS:000296752800002-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridMinna, JD=35380041500en_US
dc.identifier.scopusauthoridLam, DCL=7201749615en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats